Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hair loss drug showdown: which works better?

NCT ID NCT07190534

Disease control Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two medicines, hydroxychloroquine and methotrexate, to see which works better for frontal fibrosing alopecia, a type of scarring hair loss that mainly affects women. About 50 adults who choose to start one of these treatments will be followed for up to 48 weeks. The goal is to measure how well each medicine controls disease activity and improves quality of life, helping doctors make better treatment recommendations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from dermatology outpatient clinics at Erasmus MC University Medical Center Rotterdam. The study population consists of adults who have been diagnosed with frontal fibrosing alopecia (FFA) during routine clinical care and are considering systemic treatment with hydroxychloroquine or methotrexate.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Diagnosis of frontal fibrosing alopecia (FFA) * Willing and able to provide written informed consent * Adequate understanding of the Dutch language * No known contraindications or allergies to hydroxychloroquine (HCQ) or methotrexate (MTX) Exclusion Criteria: * Histopathological different diagnosis than FFA. * Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion. * Patients who are ineligible for the HCQ arm (due to contraindications), are automatically included in the MTX arm. Contraindications HCQ: retinopathy and/or maculopathy/myasthenia gravis/body weight less than 35 kg \- Patients who are ineligible for the MTX arm (due to contraindications), are automatically included in the HCQ arm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cicatricial alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia disorder of pilosebaceous unit frontal fibrosing alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cicatricial alopecia Frontal fibrosing alopecia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erasmus MC University Medical Center

    Rotterdam, South Holland, 3015GD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.